We are focused on discovering and developing novel therapies that disrupt the cancer treatment landscape.
2seventy bio hopes to deliver on this mission by working at the maximum speed of human thought — 270 miles per hour — to help cancer patients urgently in need. With a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to the development of new classes of cellular therapies, with the goal of creating more quality time for the patients we serve.
Disrupting Cell Therapy
Our investigational cell therapies seek to reengineer living cells to find and eliminate tumor cells in patients with cancer.
The creation of these investigational cell therapies consists of applying and combining the following approaches:
| Chimeric antigen receptor (CAR) and T cell receptor (TCR) technology, which are designed to program T cells to help recognize and kill cancer cells based on target expression on the cell surface or via the presentation of intracellular protein targets, respectively | Dual and/or multiplex targeting architectures that endeavor to enable simultaneous targeting of multiple tumor cell antigens | Pharmacologically regulated CAR technology to spare normal tissues and help preserve T cell persistence and memory formation | Engineered T cells that have the goal of enhancing anti-tumor function and reprogramming the tumor microenvironment | Lentiviral gene transfer vectors and transduction technologies that strive to deliver genetic cargo to T cells | megaTAL-based genome editing technology that seeks to enable site-specific gene addition or targeted deletion with the goal of improving the functional properties of T cells at the DNA level |
We are studying multiplex engineered cell therapies that combine our foundational lentiviral vector, CAR T, and TCR technologies with utilizing our advanced scientific toolkit in the hope of helping to address the challenge of tumor control and elimination.
These technologies include:
- Dimerizing Agent Regulated Immunoreceptor Complex (DARIC)
A pharmacologically regulated split antigen receptor architecture that comprises separate antigen targeting and signal transduction componentry with the goal of enabling pharmacological, “on-demand” control of engineered T cell responses - Dual-/Multiplex-Targeting
Dual- and multiplex-targeting antigen receptor architectures with the ability to simultaneously target multiple tumor antigens (including tumor driver and passenger proteins), thus striving to help overcome immune evasion and resistance mechanisms - Reversal of Immunosuppression
We have developed a suite of synthetic biology innovations that seek to antagonize and rewire immunosuppressive pathways to enable the targeting of tumors that have evolved to help suppress the endogenous immune system - Co-Stimulation
We pair our targeting technologies with additional costimulatory and cytokine receptor signaling domains to potentially generate qualitatively distinct, potent anti-tumor responses - Gene Editing
Our megaTAL gene editing platform enables targeted modification of the T cell genome, including gene disruption and targeted gene addition. We have also built the assays and delivery tools needed to deploy gene editing in the clinical setting - Cellular Chassis
Beyond genetic modifications, we are also developing approaches aimed at selecting for or enriching distinct T cell types for tumor targeting that may be broadly applicable to autologous or allogeneic cell therapy settings
In addition, we continue to invest upon our core foundational technologies and build upon our field-leading position in autologous engineered cell therapy products based on CAR and TCR approaches:
- Lentiviral Vector (LVV) Design and Manufacturing
With decades of experience in LVV technology, we have extensively optimized the componentry and methodology behind LVV design and manufacturing. Our product cycling engine is designed to rapidly build, test, learn, and improve - Messenger RNA (mRNA) Capabilities
mRNA offers transient gene expression, both in cells cultured ex vivo and for organ-specific in vivo delivery. We have developed clinical-scale electroporation processes for ex vivo mRNA delivery and are actively using these processes to improve T cell potency via our megaTAL gene-editing platform - Target Selection and Validation
To support novel target identification, we have developed significant in-house expertise and external collaborations in the areas of data mining, functional genomics, and primary tissue analysis, and built a full suite of target validation assays to perform confirmatory studies assessing tumor and normal tissue expression properties - Binder & Receptor Engineering
Our existing collaboration network is already delivering state-of-the-art binder capabilities that cover the full range of potential cancer targets. We have mature CAR / TCR engineering and screening capabilities, including high-throughput and automated primary T cell functional screening platforms that allow us to explore multiple interdependent parameters and rapidly optimize our targeting architectures - Manufacturing Process Innovations
With unique access to clinical trial data using CAR T therapies, we are continuously working to derive insights that inform process research directions for optimizing T cell manufacturing and for the discovery of underlying biological relationships between clinical signals and manufacturing variables
As we work to design the next generation of product candidates, we aim to address the unmet need in cancer. Together, we aim to be tougher than the toughest cancers.
